Last Update 24 Jun 26
Fair value Decreased 0.56%DSFIR: Share Buyback And New Listing Plan Will Shape Future Re Rating
The updated analyst price target for DSM-Firmenich now sits at €79.37, a marginal adjustment from €79.82. This reflects a blend of more cautious discounting and slightly revised assumptions on revenue growth, profitability, and future P/E as analysts react to recent mixed target changes across the Street.
Analyst Commentary
The recent research on DSM-Firmenich shows a wide range of views on the stock, with price targets spanning from €60 to €73 and ratings grouped around Equal Weight and more cautious stances like Underweight and Sell. For you as an investor, the key takeaway is that analysts are split on how execution and growth prospects line up with the current valuation.
Bullish Takeaways
- Bullish analysts are lifting price targets into the low €70s, which suggests they see DSM-Firmenich as roughly fairly valued to slightly attractive around those levels based on their current assumptions.
- The repeated Equal Weight ratings attached to higher targets indicate that, in their view, DSM-Firmenich is keeping pace with sector peers on earnings potential and execution, rather than lagging materially.
- Incremental target raises of a few euros at a time point to measured confidence in the company’s ability to deliver on its plans without relying on aggressive growth assumptions.
- The fact that some targets have been revised up rather than down suggests these bullish analysts see DSM-Firmenich’s fundamentals as resilient enough to support their current P/E and earnings forecasts.
Bearish Takeaways
- On the cautious side, a Sell rating paired with a cut in the price target to €65 signals concern that DSM-Firmenich’s current valuation may not fully reflect risks around demand and input costs.
- The downgrade, framed within a broader call on European chemicals with a focus on a potential downturn, puts DSM-Firmenich in a group where bearish analysts see weaker pricing power and more pressure on margins.
- The reduction of a target to €60 from €70 by JPMorgan, alongside an Underweight rating, underlines skepticism about the stock’s ability to deliver returns in line with the sector at previous valuation levels.
- Bearish analysts are tilting towards companies they describe as having stronger defensive pricing power. This implies they see DSM-Firmenich as more exposed to swings in demand and higher input costs than some peers.
What’s in the News for DSM-Firmenich
- DSM-Firmenich launched a €540 million share repurchase program, with €500 million aimed at reducing issued capital and €40 million allocated to share-based compensation plans, according to company announcements.
- The company reported 4% like for like sales growth in Q1 2026 and outlined a 2026 to 2028 action plan focused on accelerating financial performance, based on its recent update.
- DSM-Firmenich plans a dual listing on the SIX Swiss Exchange starting May 21, 2026, in addition to its existing listing, as disclosed in its capital markets communication.
- The FDA approved DSM-Firmenich’s bemotrizinol sunscreen active ingredient, marketed as PARSOL Shield, the first new sunscreen active ingredient cleared in the U.S. in more than 25 years, according to company and regulatory reports.
- DSM-Firmenich entered a partnership with Medisca to supply pharmaceutical grade vitamin APIs to U.S. compounding professionals, expanding access to ingredients produced under European cGMP standards, based on the joint announcement.
Valuation Changes for DSM-Firmenich
- Fair Value: The updated fair value estimate has edged down slightly to €79.37 from €79.82.
- Discount Rate: The discount rate has fallen modestly to 6.08% from 6.23%, indicating a slightly lower required return in the current model.
- Revenue Growth: Assumed like-for-like revenue growth has risen slightly to 3.64% from 3.56%.
- Net Profit Margin: The projected net profit margin has eased marginally to 7.49% from 7.51%.
- Future P/E: The future P/E assumption has ticked down to 27.4x from 27.7x, reflecting a slightly lower valuation multiple applied to DSM-Firmenich.
8 viewsusers have viewed this narrative update
Key Takeaways
- Focus on health-driven innovations, sustainability, and bio-based solutions enhances product differentiation, pricing power, and positions DSM-Firmenich for sustained organic growth.
- Integration synergies and increased exposure to local and regional customers boost margin improvements and revenue stability amid tightening sustainability regulations.
- Heavy reliance on regional growth, narrowing focus, and currency risks threaten DSM-Firmenich's margin stability and cash flow amid uncertain recurring organic performance.
Catalysts
About DSM-Firmenich- Provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
- The rollout of innovative, health-focused ingredients (e.g., reduced sugar, salt, and enriched with healthy components) and strong demand for preventative health products positions DSM-Firmenich to benefit from growing consumer health and wellness trends, supporting sustained organic revenue growth in key segments like Taste, Texture & Health and Health, Nutrition & Care.
- Investment in fermentation and bio-based solutions (e.g., Amberever, algal lipids, HMOs) alongside the exit from lower-margin, less sustainable businesses, is expected to lead to higher product differentiation, pricing power, and margin expansion aligned with rising preferences for sustainable alternatives.
- The successful integration of legacy DSM and Firmenich is delivering targeted cost and revenue synergies (€200 million plus €200 million vitamin transformation), with synergies continuing to flow through in coming quarters-providing further support to both revenue and EBITDA margin improvement.
- Increasing sales contribution from local and regional customers-especially in emerging markets-diversifies revenue streams, reducing the company's exposure to volume volatility at large global clients and supporting more stable, long-term top-line growth.
- DSM-Firmenich's proactive positioning for stricter sustainability regulations (bio-based, circular, reduced-emission focus) and its strength in green chemistry innovation places it ahead of industry peers, laying the groundwork for lasting margin improvement and resilience even as regulatory pressures intensify.
DSM-Firmenich Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming DSM-Firmenich's revenue will grow by 3.6% annually over the next 3 years.
- Analysts assume that profit margins will increase from 3.0% today to 7.5% in 3 years time.
- Analysts expect earnings to reach €753.3 million (and earnings per share of €3.17) by about June 2029, up from €274.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €1.3 billion in earnings, and the most bearish expecting €497.3 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.5x on those 2029 earnings, down from 69.0x today. This future PE is greater than the current PE for the GB Chemicals industry at 16.5x.
- Analysts expect the number of shares outstanding to decline by 4.54% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.08%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The company's organic sales growth (3–4% excluding Animal Nutrition & Health) is currently supported by strong performance from local and regional customers, but global accounts are softer, suggesting DSM-Firmenich may be exposed to weaker demand from larger consumer staples and possible long-term shifts in customer mix; this could limit revenue growth and margin stability if regional momentum fades.
- Ongoing exposure to foreign exchange volatility is impacting reported EBITDA and net profit (recently €25 million in a quarter), with guidance now more cautious due to currency shifts; persistent FX challenges could erode reported earnings and impair financial visibility.
- The exit of lower-margin and commodity businesses (e.g., Pinova, agro ingredients, Aroma/ANH divestment) focuses DSM-Firmenich on higher-margin core, but also narrows the company's product portfolio, making it more reliant on a concentrated set of specialized ingredients and end markets-this increases vulnerability to demand fluctuations or technological disruption, which could affect both topline growth and margins.
- Despite declared synergy achievements post-merger, a significant proportion of reported EBITDA improvement is from temporary factors like force majeure in vitamins or one-off synergies; recurring organic growth and margin expansion may underperform if these tailwinds subside, putting pressure on sustainable net margin and free cash flow.
- The company acknowledges only modest operating free cash flow (€200 million below prior period) due to working capital swings and timing issues, while still continuing substantial CapEx and share buybacks; if cash flow does not improve in line with targets, future earnings quality and leverage ratios could deteriorate.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €79.37 for DSM-Firmenich based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €103.0, and the most bearish reporting a price target of just €60.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €10.1 billion, earnings will come to €753.3 million, and it would be trading on a PE ratio of 27.5x, assuming you use a discount rate of 6.1%.
- Given the current share price of €76.34, the analyst price target of €79.37 is 3.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on DSM-Firmenich?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
€103
FV
18.6% undervalued intrinsic discount6.10%
Revenue growth p.a.
49
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€60.56
FV
38.4% overvalued intrinsic discount2.44%
Revenue growth p.a.
66
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative